Pages
- Accueil
- Code of business conduct and ethics
- Commercial Manufacturing
- Company
- Contact & quotation request
- Contact the personal data protection officer
- Cookie Policy
- Custom R&D
- Cyclization
- Generic peptides
- Investors
- Isolation
- News
- Oligo
- Peptide Modification
- Privacy policy
- Purification
- Quality at PolyPeptide
- Request our Documentation
- Search Result
- Services
- sitemap
- Subscribe to PolyPeptide Newsletter
- Supplier Code of Conduct
- Synthesis
- Contacts
Posts by category
- Category: Ad hoc announcements pursuant to Art. 53 LR
- PolyPeptide with substantial improvements in profitability and cash flow, positioned for strong growth
- Solid progress in H1 2024 – Upgrade of 2024 full-year guidance – Mid-term target to double 2023 revenue by 2028
- PolyPeptide with record revenue growth of 43% in H2 2023 versus H1 2023; operational improvements yielding increased profitability and cash flow
- Transformational progress taking shape, profitability impacted by rapid expansion – appointment of Marc Augustin as new CFO
- PolyPeptide delivers revenue of around EUR 132 million for H1 – expects net loss for H1 and full year 2023
- PolyPeptide appoints Juan-José Gonzalez as CEO and announces change of CFO
- PolyPeptide reports weaker performance in 2022 – expects growth to recover in the second half of 2023
- CEO of PolyPeptide resigns
- PolyPeptide signs significant commercial agreement
- PolyPeptide provides market update
- PolyPeptide with encouraging progress within custom projects pipeline – however with lower profitability in the first half of 2022
- PolyPeptide provides market update
- PolyPeptide achieves strong profitable growth in 2021
- PolyPeptide Group appoints Neil Thompson as Director Global Sales and Marketing and member of the Executive Committee, succeeding Jan Christensen
- Results of Accelerated Bookbuild Offering of 1,500,000 Existing Shares in PolyPeptide Group AG
- PolyPeptide reports strong H1 2021 revenue growth and operating leverage amidst favorable market environment and encouraging business trends
- PolyPeptide Group appoints Christina Del Vecchio as General Counsel and member of the Executive Committee
- PolyPeptide Group announces the exercise of the full over-allotment option
- Category: Media releases
- PolyPeptide announces expansion of existing credit facilities
- PolyPeptide announces results of the annual General Meeting 2025
- PolyPeptide publishes invitation to the annual General Meeting 2025
- Cytovance Biologics and PolyPeptide Announce Collaboration for Microbial and Mammalian-Expressed Peptide Drugs
- Doubling of production capacity at the manufacturing site in Malmö
- Large-scale SPPS capacity in Braine-l’Alleud starts production
- PolyPeptide appoints Chief Commercial Officer
- PolyPeptide and Donaldson collaborate to develop solvent recovery system for peptide purification
- PolyPeptide announces results of the annual General Meeting 2024
- PolyPeptide publishes invitation to the annual General Meeting 2024
- PolyPeptide signs scientific collaboration agreement
- PolyPeptide secures revolving credit facility
- PolyPeptide and Numaferm announce partnership to leverage their expertise for the more sustainable production of peptide-based APIs
- PolyPeptide announces results of the annual General Meeting 2023
- PolyPeptide publishes invitation to the annual General Meeting 2023
- Monika Casanova joining PolyPeptide as CHRO and member of the PMC
- PolyPeptide announces results of the annual General Meeting 2022
- PolyPeptide publishes invitation to the annual General Meeting 2022
- PolyPeptide customer Cara Therapeutics with FDA approval for novel treatment of moderate-to-severe pruritus in hemodialysis patients
- PolyPeptide Group appoints Raymond De Vré as new Chief Executive Officer
- PolyPeptide Group Selected by Novavax to Manufacture Critical Intermediates of Matrix-M™ Adjuvant for its COVID-19 Vaccine
- Category: Business news
- Alzinova Advances ALZ-101 Development with Drug Substance Release, Paving the Way for Phase 2 Clinical Trial
- Vinnova grant awarded to joint project between PolyPeptide and Red Glead Discovery for developing a more sustainable manufacturing method for a GLP-1 agonist.
- PolyPeptide launches new “Innovation Lab”
- FluoGuide reaches milestone with FG001 for phase III clinical supply
- PolyPeptide wins Malmö Life Science Business Award
- Efficient and sustainable solutions for large scale peptide manufacturing
- Proclamation honoring Jane Salik upon her retirement
- Stock exchange listing
- PolyPeptide News Flash, #1, 2021
- Therapeutic indications for the PolyPeptide Group pipeline projects 2020
- New in-silico development tools support more efficient process design
- PolyPeptide News Flash, #3, 2020
- Capacity Expansion through Investment and Innovation
- PolyPeptide News Flash, #2, 2020
- Information Letter on COVID-19
- New member of the Medicon Valley Alliance
- PolyPeptide News Flash February 2020
- Innovation and Technology
- PolyPeptide News Flash October
- Press release: the start of a research collaboration program with IBMM in Montpellier, France
- Symposium on Preparative and Process Scale HPLC, MCC and SFC 2019
- Book your meeting with PolyPeptide at CPhI worldwide – Frankfurt, Germany 5-7 November 2019
- 100% sustainable energy from wind turbines at PolyPeptide Sweden
- PolyPeptide attends TIDES Europe – Amsterdam, November 7th and 8th
- Category: Expert views
- Expanding the Reach of Sustainable Solid-Phase Peptide Synthesis
- Impurities in Peptide Drug Substance and Challenges Faced during Registration (in US, EU, Brazil and China Markets) and Commercial Phase
- Peptide Manufacturing: Rethinking the Technology Platform for Large Scale Demand
- PolyPeptide supports landmark publication on sustainable peptide synthesis
- Research article: Sustainable PFAS-free alternatives for TFA in SPPS
- Advancing Sustainable Peptide Synthesis by Solvent Quality Control: Understanding and Mitigating Hydroperoxide in 1-Butyl-2-pyrrolidinone (NBP)
- Trending topics at PolyPeptide
- Research article: Synthesis of Peptides by Reactive Extrusion. Application to the Continuous and Solventless Preparation of Aspartame.
- PolyPeptide participates in industry effort to advance sustainability
- Green Chemistry Articles of Interest to the Pharmaceutical Industry
- Green Chemistry Articles of Interest to the Pharmaceutical Industry
- Quality Assessment and Minimizing Racemization, Precipitation, and Radical-Induced Side Reactions by TBEC/Oxyma Couplings in an Environmentally Sensible Solvent
- Trending topics at PolyPeptide
- Assessment of Sulfur Impurities in GMP-Grade Diisopropylcarbodiimide and Their Impact on Coupling Reagent-Induced Side Reactions in Peptide Synthesis
- Green Chemistry Articles of Interest to the Pharmaceutical Industry
- Developing the Toolbox for Sustainable Peptide Manufacturing
- Overcoming Oligonucleotide Manufacturing Challenges
- Chemical strategies in extending half-lives of therapeutic peptides
- From 10 grams to several hundred – A case study in peptide GMP process development
- Green Chemistry Articles of Interest to the Pharmaceutical Industry
- Green Chemistry Articles of Interest to the Pharmaceutical Industry
- Environmentally Sensible Organocatalytic Fmoc/t Bu Solid-Phase Peptide Synthesis
- SPPS: Process improvements to reduce solvent consumption
- Circular Aqueous Fmoc/t-Bu Solid-Phase Peptide Synthesis
- Downstream Processes for peptide manufacturing: Optimization strategy and latest technical trends
- Green Chemistry Articles of Interest to the Pharmaceutical Industry
- Minimizing HCN in DIC/Oxyma-Mediated Amide Bond-Forming Reactions
- Minimizing HCN in DIC/Oxyma-Mediated Amide Bond-Forming Reactions
- Selection of publications on significant advances in production and use of Peptides
- Sustainable, cost-efficient manufacturing of therapeutic peptides using chemo-enzymatic peptide synthesis (CEPS)
- QA interview: Focus innovation
- ReGreen SPPS: enabling circular chemistry in environmentally sensible solid-phase peptide synthesis
- Economic and environmental factors affecting the sustainability of peptide therapeutic manufacturing
- A Holistic Quality Control Strategy for Peptide Active Pharmaceutical Ingredients (APIs)
- Poster: Benzylthiols as scavengers in TFA cleavages of peptide resins
- 2D green SPPS: green solvents for on-resin removal of acid sensitive protecting groups and lactamization
- Panel discussion on peptides
- Aspects of greening peptide chemistry within the pharmaceutical manufacturing industry
- Advanced SPPS
- Panel discussion on pharma and chemical supply chain
- Needle-to-needle’: Manufacturing NeoAntigen peptides
- Poster: Towards cost-efficient, scalable green SPPS
- 1,4-Benzenedimethanethiol (1,4-BDMT) as a scavenger for greener peptide resin cleavages
- Suitable solvent for cost-efficient green SPPS
- Considerations for multi-product manufacturing facilities
- Designing quality into therapeutic peptide manufacturing
- Process validation: Manufacturing peptide APIs
- Control strategies for synthetic therapeutic peptide APIs – Part III: Manufacturing process considerations
- Control strategies for synthetic therapeutic peptide APIs – Part II: Raw material considerations
- Control strategies for synthetic therapeutic peptide APIs – Part I: Analytical consideration
- The ideal peptide plant
- Bioconjugates: The adaptable challenge
- Meeting the growing demand for peptide therapeutics
- Poster: Focus on Controlling Non-peptide Impurities in Peptide API Manufacturing
- Challenges for therapeutic peptides Part 1: On the inside, looking out
- Challenges for therapeutic peptides part 2: Delivery systems
- Challenges in technology transfers of API manufacturing to India
- Building global QA system and compliance
- The future of peptide development in the pharmaceutical industry
- Quality by design, a peptide CMO approach
- DTT reacts with TFA to form a novel bicyclic dithioorthoester
- Building business in therapeutic peptides
- Are low-priced peptides affordable?
- A peptide specialist
- Quality control in peptide manufacturing: specifications for GMP peptides
- Aspects of industrial purification of peptides using large scale chromatography
- Large-Scale synthesis of peptides
Events
- TIDES EU
- PTS Peptide Therapeutics Symposium
- Chem Outsourcing
- Peptide Aggregation in Manufacturing
- CPHI
- NLS days
- Boulder Peptide Symposium
- HubXchange
- Bio International Convention
- APS American Peptide Symposium
- IOPC - International Oligonucleotides and Peptides Conference
- Full year results conference 2025
- Formation Emploi Alsace
- KULA career fair of the Guild of Chemical Engineering and Biotechnology 2025
- CPHI North America
- TIDES USA
- Swiss Biotech Day
- DCAT week
- NextGen BioMed 2025
- TIDES Asia
- Biotech Showcase
- TIDES EU
- Peptide Therapeutic Symposium
- CPHI Milan 2024
- Boulder Peptide Symposium
- Peptoid Summit
- NLS days
- European Peptide Symposium 2024
- RNA Leaders US
- Half year results 2026
- General Meeting 2026
- Full year results 2025
- IOPC - International Oligonucleotides and Peptides Conference
- hubXchange’s Boston Oligonucleotide Therapeutics 2024
- European Peptide Synthesis Conference 2024
- Pharma PPM Toolbox Conference
- Jobsday Chimie, Pharma, Health & Biotech
- Half year results conference 2025
- Full year results conference 2024
- Half year results conference 2024, 09:30am
- Full-year results conference 2023 at 10:30am
- KULA - career fair of the Guild of Chemical Engineering and Biotechnology
- Bio International Convention
- TIDES USA
- Swiss Biotech Day
- CPhI North America
- In-cosmetics global
- AACR Annual Meeting
- TIDES Asia
- BIO Europe Spring
- DCAT week 2024
- RNA leaders Europe
- Half year results 2025
- General Meeting 2025 - 9 April 2025
- Full year results 2024
- Biologics UK
- Gordon Research Conference - Exploring Peptides as Natural and Unnatural Scaffolds for Discovery
- HubXchange Oligonucleotide Therapeutics
- Biotech Showcase
- BIO Europe - Partnering
- BIO Japan
- TIDES Europe
- NLS Days
- GFPP meeting
- Audio webcast & conference call market update
- CphI Barcelona 2023
- Peptide Therapeutics Symposium
- Boulder Peptide Symposium
- RNA leaders USA Congress
- Swiss Biotech Day
- HubXchange Europe
- Bio International Convention
- IOPC
- TIDES US
- CPhI North America
- JobDays
- Date of close share register
- Bioscience Talent Connections, Career Fair
- In-cosmetics global
- HubXchanges
- BIO Europe Spring
- DCAT week
- RNA leaders Europe
- TIDES Asia
- RNA Therapeutics
- Half year results 2024, 07:00am
- General Meeting 2024
- Full year results 2023 publication at 07:00am
- Half year results 2023
- Market Update with Audio Webcast and Conference Call
- HubXchange - Oligonucleotides
- Biotech Showcase
- Baader Helvea Swiss Equities Conference
- Octavian Swiss Seminar
- ARKAD
- Berenberg European Conference
- Credit Suisse Equity Forum Switzerland 2022
- Jefferies Healthcare Conference
- ZKB Swiss Equities Conference 2022
- Demo event
- Demo event
- Demo event
- Half year results conference 2022 at 09:30am
- Full year results 2022
- Baader Swiss Equities Conference, digital
- Octavian Seminar, Flims, CH
- FY 2021 Results
- FY2021 Results conference
- Last trading day incl. dividend entitlement
- Dividend ex-date
- Dividend record date
- Dividend payment date
- Half year results 2022 at 07:00am
- 2021 Half-Year Results
- Morgan Stanley 19th Annual Global Healthcare Conference
- ZKB Swiss Equities Conference
- 14th Credit Suisse Equity Forum Switzerland
- Berenberg Swiss Seminar, digital
- General Meeting 2023
- General Meeting 2022